Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
-
Source:
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma
تفاصيل العنوان
-
Source:
A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in RemissionUrban-Wojciuk Z, Graham A, Barker
تفاصيل العنوان
-
Authors :
Giselle Sholler, Beat Childhood Cancer Chair
-
Source:
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
تفاصيل العنوان
-
Source:
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
تفاصيل العنوان
-
Source:
A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With EtoposideSaulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur
تفاصيل العنوان
-
Source:
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
تفاصيل العنوان
-
Source:
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by
تفاصيل العنوان
